Interleukin-10 Demonstrates Antitumor Activity in Patients With RCC

Share this content:
Interleukin-10 (AM0010) demonstrates antitumor activity, with an acceptable toxicity profile, in patients with renal cell carcinoma.
Interleukin-10 (AM0010) demonstrates antitumor activity, with an acceptable toxicity profile, in patients with renal cell carcinoma.

Interleukin-10 (AM0010) demonstrates antitumor activity, with an acceptable toxicity profile, in patients with renal cell carcinoma (RCC), according to a study published in the Journal of Clinical Oncology.1

Researchers evaluated patients who were treated with AM0010 in a dose-escalation study, as well as a RCC dose-expansion cohort, with primary endpoints being safety and tolerability. Secondary endpoints were clinical activity and immune activation.

In total, 33 patients through the dose-escalation cohort and 18 patients through the dose-expansion cohort were examined. The treatment was tolerated in a heavily pretreated patient population.

Common treatment-related adverse events included anemia, fatigue, thrombocytopenia, fever, and injection site reactions, with grade 3 to 4 anemia or thrombocytopenia observed in 5 patients. Grade 3 to 4 nonhematopoietic treatment-related adverse events included rash and transaminitis in 5 of the patients in the dose-escalation cohort. Most treatment-related adverse events were transient or reversible.

RELATED: Functional Health May Be Strong Predictor of Survival in Elderly Patients With Kidney Cancer

AM0010 led to systemic immune activation with an elevation in immune-stimulatory cytokines, as well as a reduction in transforming growth factor beta in the serum.

Reference

  1. Naing A, Papadopoulous KP, Autio KA, et al. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol. 2016 Aug 15. doi: 10.1200/JCO.2016.68.1106 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters